Clinical Study Results

Seeing Machines Limited
30 August 2006


30 August 2006
                            SEEING MACHINES LIMITED
                      ('Seeing Machines' or 'the Company')

                    GLAUCOMA PROJECT CLINICAL STUDY RESULTS


Seeing Machines Limited (AIM: SEE), a leading developer of advanced computer
based imaging software systems, recently concluded the initial phase of a second
clinical study (CT2) of the glaucoma testing device.  The purpose of this
investigation was to build on the positive results of the CT1 clinical study
announced in January 2006 by further exploring the operational parameters of the
device's behaviour in a clinical setting.

Importantly, the outcome of this work has clearly illuminated a small number of
design parameters that need further investigation prior to the introduction of
the device.  Accordingly an additional clinical study (T13) has been instituted
that will explore these issues allowing for a resumption of the second phase of
the major CT2 study.  The T13 study will commence today.

The Company is continuing to progress the other commercialisation activities
required to bring the device to market including regulatory approval, hardware
design and software development.  All of these activities are supported by the
recently awarded Commercial Ready Grant from the Australian Government which
will allow for the expedited completion of the work.   The Company remains
committed to releasing the glaucoma diagnostic device during 2007.


Enquiries:

 Seeing Machines Limited       Insinger de Beaufort     Parkgreen Communications
 Nick Cerneaz, CEO             Simon Fox                Justine Howarth /
                                                        Victoria Thomas
 [phone]           [phone]     [phone]
 www.seeingmachines.com


                      This information is provided by RNS
            The company news service from the London Stock Exchange